Wealth Alliance Advisory Group LLC Raises Position in Eli Lilly and Company $LLY

Wealth Alliance Advisory Group LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 18.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,106 shares of the company’s stock after purchasing an additional 964 shares during the quarter. Eli Lilly and Company makes up approximately 1.1% of Wealth Alliance Advisory Group LLC’s portfolio, making the stock its 23rd biggest holding. Wealth Alliance Advisory Group LLC’s holdings in Eli Lilly and Company were worth $6,562,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after buying an additional 551,659 shares during the period. State Street Corp grew its stake in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after acquiring an additional 219,590 shares during the period. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Wellington Management Group LLP increased its holdings in Eli Lilly and Company by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after acquiring an additional 574,229 shares during the last quarter. Finally, Capital International Investors increased its holdings in Eli Lilly and Company by 6.1% in the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock worth $7,628,447,000 after acquiring an additional 579,381 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Leerink Partners reduced their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research note on Monday. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $875.00 to $880.00 and gave the company a “neutral” rating in a research report on Friday, April 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, TD Cowen lifted their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,216.52.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $874.14 on Wednesday. The company has a 50 day moving average of $952.17 and a 200 day moving average of $986.25. The stock has a market cap of $825.91 billion, a P/E ratio of 38.09, a P/E/G ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the prior year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 33.9 EPS for the current fiscal year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Ajax Therapeutics for up to $2.3B, adding a JAK2 inhibitor for myelofibrosis and expanding its oncology/hematology pipeline—a diversification away from GLP?1 reliance. Lilly Agrees To Buy Ajax Therapeutics For Up To $2.3 Billion
• Positive Sentiment: Lilly struck a multi?program AI/genetic?medicine deal with Profluent worth up to ~$2.25B to accelerate DNA?editing and enzyme design—this boosts R&D productivity potential and could lift long?term valuation if programs advance. Eli Lilly’s AI Genetic Medicine Deal And What It Means For Valuation
• Positive Sentiment: Analysts remain bullish overall (e.g., reiterated Overweight/price targets following recent acquisitions), providing support that fundamentals and pipeline diversification justify a premium. Analysts Reiterate Bullish Outlook on Eli Lilly
• Neutral Sentiment: Investors will watch Q1 results for high?level trends, but management won’t provide detailed Foundayo launch metrics in the earnings release—so the quarter may not settle near?term launch questions. Eli Lilly investors are eager for Foundayo insight after early launch data
• Negative Sentiment: Early launch data show Lilly’s oral Foundayo is tracking behind Novo Nordisk’s Wegovy pill (Citi/IQVIA prescription data), raising concerns about market share, pricing pressure and near?term revenue trajectory for GLP?1s. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: Competitor Boehringer reported late?stage obesity results showing meaningful weight loss (~16.6%), adding competitive pressure to Lilly’s obesity franchise and intensifying investor scrutiny of future GLP?1 pricing and share. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Leerink lowered its price target (from $1,296 to $1,058), signaling some analyst recalibration of upside given near?term launch risks—this can amplify selling pressure even as many analysts remain constructive. Leerink Partners adjusts PT on Eli Lilly

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.